Biologic treatments in Sjögren's syndrome

Presse Medicale

Volumn 41, Issue 9 PART2, 2012, Pages

  Bowman, Simon ^a   Barone, Francesca ^b  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; APRIL PROTEIN; ARTIFICIAL TEAR; ASCORBIC ACID; ATACICEPT; AZATHIOPRINE; B CELL ACTIVATING FACTOR; BELIMUMAB; CXCL13 CHEMOKINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DOXORUBICIN; EPRATUZUMAB; HYDROXYCHLOROQUINE; INFLIXIMAB; INTERLEUKIN 6; LEFLUNOMIDE; MACROPHAGE DERIVED CHEMOKINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OCRELIZUMAB; PILOCARPINE; PLACEBO; PREDNISOLONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VINCRISTINE;

ARTHRALGIA; B CELL LYMPHOMA; BIOLOGICAL THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; COMBINATION CHEMOTHERAPY; CRYOGLOBULINEMIA; DRUG EFFICACY; DRUG FEVER; DRUG TOLERABILITY; DRY EYE; EYE CARE; FATIGUE; HEALTH CARE COST; HUMAN; IMMUNE SYSTEM; INFECTION RISK; LARGE CELL LYMPHOMA; LOW DRUG DOSE; LYMPHOMA; MONOTHERAPY; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; PAROTID GLAND DISEASE; PATHOGENESIS; PRIMARY SJOEGREN SYNDROME; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; QUALITY OF LIFE; RHEUMATOID ARTHRITIS; RISK FACTOR; SHORT SURVEY; SJOEGREN SYNDROME; SYMPTOMATOLOGY; SYSTEMIC LUPUS ERYTHEMATOSUS; TH17 CELL; TREATMENT INDICATION; TREATMENT RESPONSE; VASCULITIS; VISUAL ANALOG SCALE;

EID: 84865973603     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2012.05.024     Document Type: Short Survey

References (150)

1. Jonsson R., Bowman S.J., Gordon T.P. Sjögren's syndrome. Arthritis and allied conditions. Ch. 78 2005, 1681-1705. Lippincott Williams & Wilkins. 15th ed. W.J. Koopman, L.W. Moreland (Eds.).
2. Kruize A.A., Hené R.J., van der Heide A., Bodeutsch C., de Wilde P.C., van Bijsterveld O.P., et al. Long-term follow-up of patients with Sjögren's syndrome. Arthritis Rheum 1996, 39:297-303.
3. Voulgarelis M., Dafni U.G., Isenberg D.A., Moutsopoulos H.M. Malignant lymphoma in primary Sjögren's syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjögren's Syndrome. Arthritis Rheum 1999, 42:1765-1772.
4. Theander E., Henriksson G., Ljungberg O., Mandl T., Manthorpe R., Jacobsson L.T. Lymphoma and other malignancies in primary Sjögren's syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis 2006, 65:796-803.
5. Bowman S.J., Ibrahim G.H., Holmes G., Hamburger J., Ainsworth J.R. Estimating the prevalence among Caucasian women of primary Sjögren's syndrome in two general practices in Birmingham, UK. Scand J Rheumatol 2004, 33:39-43.
6. Segal B., Bowman S.J., Fox P.C., Vivino F.B., Murukutla N., Brodscholl J., et al. Primary Sjögren's Syndrome: health experiences and predictors of health quality among patients in the United States. Health Qual Life Outcomes 2009, 7:46.
7. Bowman S.J. Fatigue, dryness and quality of life as clinical trial outcomes in primary Sjögren's syndrome. Sjögren's Syndrome - practical guidelines to diagnosis and therapy. Ch. 21 2011, 357-372. Springer. R.I. Fox, C.M. Fox (Eds.).
8. Callaghan R., Prabu A., Allan R.B., Clarke A.E., Sutcliffe N., Pierre Y.S., et al. Direct healthcare costs and predictors of costs in patients with primary Sjögren's syndrome. Rheumatology (Oxford) 2007, 46:105-111.
9. Bowman S.J., Pierre St., Sutcliffe Y., Isenberg N., Goldblatt D.A., Price F., et al. Estimating indirect costs in primary Sjögren's syndrome. J Rheumatol 2010, 37:1010-1015.
10. Sall K., Stevenson O.D., Mundorf T.K., Reis B.L. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology 2000, 107:631-639.
11. Vivino F.B., Al-Hashimi I., Khan Z., LeVeque F.G., Salisbury P.L., Tran-Johnson T.K., et al. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjögren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01 Study Group. Arch Intern Med 1999, 159:174-181.
12. Fife R.S., Chase W.F., Dore R.K., Wiesenhutter C.W., Lockhart P.B., Tindall E., et al. Cevimeline for the treatment of xerostomia in patients with Sjögren syndrome: a randomized trial. Arch Intern Med 2002, 162:1293-1300.
13. Kruize A.A., Hené R.J., Kallenberg C.G., van Bijsterveld O.P., van der Heide A., Kater L., et al. Hydroxychloroquine treatment for primary Sjögren's syndrome: a two-year double blind crossover trial. Ann Rheum Dis 1993, 52:360-364.
14. Tishler M., Yaron I., Shirazi I., Yaron M. Hydroxychloroquine treatment for primary Sjögren's syndrome: its effect on salivary and serum inflammatory markers. Ann Rheum Dis 1999, 58:253-256.
15. Fox R.I., Dixon R., Guarrasi V., Krubel S. Treatment of primary Sjögren's syndrome with hydroxychloroquine: a retrospective, open-label study. Lupus 1996, 5(Suppl. 1):S31-S36.
16. Rihl M., Ulbricht K., Schmidt R.E., Witte T. Treatment of sicca symptoms with hydroxychloroquine in patients with Sjögren's syndrome. Rheumatology (Oxford) 2009, 48:796-799.
17. Yavuz S., Asfuroglu E., Bicakcigil M., Toker E. Hydroxychloroquine improves dry eye symptoms of patients with primary Sjögren's syndrome. Rheumatol Int 2001, 31:1045-1049.
18. Dawson L.J., Caulfield V.L., Stanbury J.B., Field A.E., Christmas S.E., Smith P.M. Hydroxychloroquine therapy in patients with primary Sjögren's syndrome may improve salivary gland hypofunction by inhibition of glandular cholinesterase. Rheumatology (Oxford) 2005, 44:449-455.
19. Fox P.C., Datiles M., Atkinson J.C., Macynski A.A., Scott J., Fletcher D., et al. Prednisone and piroxicam for treatment of primary Sjögren's syndrome. Clin Exp Rheumatol 1993, 11:149-156.
20. Price E.J., Rigby S.P., Clancy U., Venables P.J. A double blind placebo controlled trial of azathioprine in the treatment of primary Sjögren's syndrome. J Rheumatol 1998, 25:896-899.
21. Skopouli F.N., Jagiello P., Tsifetaki N., Moutsopoulos H.M. Methotrexate in primary Sjögren's syndrome. Clin Exp Rheumatol 1996, 14:555-558.
22. Drosos A.A., Skopouli F.N., Galanopoulou V.K., Kitridou R.C., Moutsopoulos H.M. Cyclosporin a therapy in patients with primary Sjögren's syndrome: results at one year. Scand J Rheumatol Suppl 1986, 61:246-249.
23. van Woerkom J.M., Kruize A.A., Geenen R., van Roon E.N., Goldschmeding R., Verstappen S.M., et al. Safety and efficacy of leflunomide in primary Sjögren's syndrome: a phase II pilot study. Ann Rheum Dis 2007, 66:1026-1032.
24. Willeke P., Schlüter B., Becker H., Schotte H., Domschke W., Gaubitz M. Mycophenolate sodium treatment in patients with primary Sjögren syndrome: a pilot trial. Arthritis Res Ther 2007, 9:R115.
25. Delalande S., de Seze J., Fauchais A.L., Hachulla E., Stojkovic T., Ferriby D., et al. Neurologic manifestations in primary Sjögren syndrome: a study of 82 patients. Medicine (Baltimore) 2004, 83:280-291.
26. Voulgarelis M., Ziakas P.D., Papageorgiou A., Baimpa E., Tzioufas A.G., Moutsopoulos H.M. Prognosis and outcome of non-Hodgkin lymphoma in primary Sjögren syndrome. Medicine (Baltimore) 2012, 91:1-9.
27. Pollard R.P., Pijpe J., Bootsma H., Spijkervet F.K., Kluin P.M., Roodenburg J.L., et al. Treatment of mucosa-associated lymphoid tissue lymphoma in Sjögren's syndrome: a retrospective clinical study. J Rheumatol 2011, 38:2198-2208.
28. Marcus R., Imrie K., Belch A., Cunningham D., Flores E., Catalano J., et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005, 105:1417-1423.
29. Mounier N., Briere J., Gisselbrecht C., Emile J.F., Lederlin P., Sebban C., et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 2003, 101:4279-4284.
30. Pijpe J., van Imhoff G.W., Spijkervet F.K., Roodenburg J.L., Wolbink G.J., Mansour K., et al. Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study. Arthritis Rheum 2005, 52:2740-2750.
31. Meijer J.M., Pijpe J., Vissink A., Kallenberg C.G., Bootsma H. Treatment of primary Sjögren syndrome with rituximab: extended follow-up, safety and efficacy of retreatment. Ann Rheum Dis 2009, 68:284-285.
32. Seror R., Sordet C., Guillevin L., Hachulla E., Masson C., Ittah M., et al. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome. Ann Rheum Dis 2007, 66:351-357.
33. Gibbons L.J., Hyrich K.L. Biologic therapy for rheumatoid arthritis: clinical efficacy and predictors of response. BioDrugs 2009, 23(2):111-124.
34. Stohl W., Hiepe F., Latinis K.M., Thomas M., Scheinberg M.A., Clarke A., et al. Belimumab reduces autoantibodies, normalizes low complement and reduces select B-cell populations in patients with systemic lupus erythematosus. Arthritis Rheum 2012, 10.1002/art.34400.
35. Bowman S.J., Booth D.A., Platts R.G., the UK Sjögren's Interest Group Measurement of fatigue and discomfort in primary Sjögren's syndrome using a new questionnaire tool. Rheumatology (Oxford) 2004, 43:758-764.
36. Bowman S.J., Booth D.A., Platts R.G., Field A., Rostron J., the UK Sjögren's Interest Group Validation of the Sicca Symptoms Inventory for clinical studies of Sjögren's syndrome. J Rheumatol 2003, 30:1259-1266.
37. Bowman S.J., Hamburger J., Richards A., Barry R.J., Rauz S. Patient-reported outcomes in primary Sjögren's syndrome: comparison of the long and short versions of the Profile of Fatigue and Discomfort-Sicca Symptoms Inventory. Rheumatology (Oxford) 2009, 48:140-143.
38. Seror R., Ravaud P., Mariette X., Bootsma H., Theander E., Hansen A., et al. EULAR Sjögren's syndrome patients reported index (ESSPRI): development of a consensus index for primary Sjögren's syndrome. Ann Rheum Dis 2011, 70:968-972.
39. Seror R., Bootsma H., Bowman S.J., Dörner T., Gottenberg J.E., Mariette X., et al. Outcome measures for primary Sjögren's syndrome. J Autoimmun 2012, http://dx.doi.org/10.1016/j.jaut.2012.01.013.
40. Seror R., Ravaud P., Bowman S.J., Baron G., Tzioufas A., Theander E., et al. EULAR Sjögren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjögren's syndrome. Ann Rheum Dis 2010, 69:1103-1109. [Erratum in: Ann Rheum Dis 2011;71:880].
41. Seror R., Mariette X., Bowman S., Baron G., Gottenberg J.E., Boostma H., et al. Accurate detection of changes in disease activity in primary Sjögren's syndrome by the European League against Rheumatism Sjögren's syndrome disease activity index. Arthritis Care Res 2010, 62:551-558.
42. Vitali C., Palombi G., Baldini C., Benucci M., Bombardieri S., Covelli M., et al. Sjögren's Syndrome Disease Damage Index and disease activity index: scoring systems for the assessment of disease damage and disease activity in Sjögren's syndrome, derived from an analysis of a cohort of Italian patients. Arthritis Rheum 2007, 56:2223-2231.
43. Bowman S.J., Sutcliffe N., Isenberg D.A., Goldblatt F., Adler M., Price E., et al. Sjögren's Systemic Clinical Activity Index (SCAI): a systemic disease activity measure for use in clinical trials in primary Sjögren's syndrome. Rheumatology (Oxford) 2007, 46:1845-1851.
44. Barry R.J., Sutcliffe N., Isenberg D.A., Price E., Goldblatt F., Adler M., et al. The Sjögren's Syndrome Damage Index--a damage index for use in clinical trials and observational studies in primary Sjögren's syndrome. Rheumatology (Oxford) 2008, 47:1193-1198.
45. Galloway J.B., Hyrich K.L., Mercer L.K., Dixon W.G., Ustianowski A.P., Helbert M., et al. BSR Biologics Register. Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2011, 70:1810-1814.
46. Dixon W.G., Hyrich K.L., Watson K.D., Lunt M., Galloway J., Ustianowski A., et al. BSR Biologics Register. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010, 69:522-528.
47. Salliot C., Dougados M., Gossec L. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis 2009, 68:25-32.
48. Furst D.E. The risk of infections with biologic therapies for rheumatoid arthritis. Semin Arthritis Rheum 2010, 39:327-346.
49. Tak P.P., Mease P.J., Genovese M.C., Kremer J., Haraoui B., Tanaka Y., et al. Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial. Arthritis Rheum 2012, 64:360-370.
50. Molloy E.S., Calabrese L.H. Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases. Arthritis Rheum 2009, 60:3761-3765.
51. Carson K.R., Evens A.M., Richey E.A., Habermann T.M., Focosi D., Seymour J.F., et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009, 113:4834-4840.
52. Bharat A., Xie F., Baddley J.W., Beukelman T., Chen L., Calabrese L., et al. Incidence and risk factors for Progressive Multifocal Leukoencephalopathy among patients with selected rheumatic diseases. Arthritis Care Res 2012, 64:612-615.
53. Looney R.J. Will targeting B cells be the answer for Sjögren's syndrome?. Arthritis Rheum 2007, 56:1371-1377.
54. Salomonsson S., Jonsson M.V., Skarstein K., Brokstad K.A., Hjelmström P., Wahren-Herlenius M., et al. Cellular basis of ectopic germinal center formation and autoantibody production in the target organ of patients with Sjögren's syndrome. Arthritis Rheum 2003, 48:3187-3201.
55. Jousse-Joulin S., Devauchelle-Pensec V., Morvan J., Guias B., Pennec Y., Pers J.O., et al. Ultrasound assessment of salivary glands in patients with primary Sjögren's syndrome treated with rituximab: quantitative and Doppler waveform analysis. Biologics 2007, 1:311-319.
56. Botez S.A., Herrmann D.N. Prolonged remission of a demyelinating neuropathy in a patient with lymphoma and Sjögren's syndrome after rituximab therapy. J Clin Neuromuscul Dis 2010, 11:127-131.
57. Voulgarelis M., Giannouli S., Anagnostou D., Tzioufas A.G. Combined therapy with rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) for Sjögren's syndrome-associated B-cell aggressive non-Hodgkin's lymphomas. Rheumatology (Oxford) 2004, 43:1050-1053.
58. Vitali C., Bombardieri S., Jonsson R., Moutsopoulos H.M., Alexander E.L., Carsons S.E., et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002, 61:554-558.
59. Pers J.O., Devauchelle V., Daridon C., Bendaoud B., Le Berre R., Bordron A., et al. BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren's syndrome. Arthritis Rheum 2007, 56:1464-1477.
60. Pijpe J., Meijer J.M., Bootsma H., van der Wal J.E., Spijkervet F.K.L., Kallenberg C.G.M., et al. Clinical and histologic evidence of salivary gland restoration supports the efficacy of rituximab treatment in Sjögren's syndrome. Arthritis Rheum 2009, 60:3251-3256.
61. Abdulahad W.H., Meijer J.M., Kroese F.G., Meiners P.M., Vissink A., Spijkervet F.K., et al. B cell reconstitution and T helper cell balance after rituximab treatment of active primary Sjögren's syndrome: a double-blind, placebo-controlled study. Arthritis Rheum 2011, 63:1116-1123.
62. Gottenberg J.E., Guillevin L., Lambotte O., Combe B., Allanore Y., Cantagrel A., et al. Club Rheumatismes et Inflammation (CRI). Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 2005, 64:913-920.
63. Devauchelle-Pensec V., Pennec Y., Morvan J., Pers J.O., Daridon C., Jousse-Joulin S., et al. Improvement of Sjögren's syndrome after two infusions of rituximab (anti-CD20). Arthritis Care Res 2007, 57:310-317.
64. Levesque M.C., Luning Prak N., Clair St., Meng E.W., Du W., McNair Y.Z., et al. Longitudinal analysis of lymphocyte subsets in patients with primary Sjögren's syndrome (pSS) treated with rituximab: results from an open-label clinical trial. Arthritis Rheum 2007, 56(Supplement):S445.
65. Dass S., Bowman S.J., Vital E.M., Ikeda K., Pease C.T., Hamburger J., et al. Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann Rheum Dis 2008, 67:1541-1544.
66. Meijer J.M., Meiners P.M., Vissink A., Spijkervet F.K., Abdulahad W., Kamminga N., et al. Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010, 62:960-968.
67. Steinfeld S.D., Tant L., Burmester G.R., Teoh N.K., Wegener W.A., Goldenberg D.M., et al. Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study. Arthritis Res Ther 2006, 8:R129.
68. Moore P.A., Belvedere O., Orr A., Pieri K., LaFleur D.W., Feng P., et al. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 1999, 285:260-263.
69. Schneider P., MacKay F., Steiner V., Hofmann K., Bodmer J.L., Holler N., et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 1999, 189:1747-1756.
70. Mackay F., Woodcock S.A., Lawton P., Ambrose C., Baetscher M., Schneider P., et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999, 190:1697-1710.
71. Mariette X., Roux S., Zhang J., Bengoufa D., Lavie F., Zhou T., et al. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren's syndrome. Ann Rheum Dis 2003, 62:168-171.
72. Pers J.O., Daridon C., Devauchelle V., Jousse S., Saraux A., Jamin C., et al. BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann N Y Acad Sci 2005, 1050:34-39.
73. Jonsson M.V., Szodoray P., Jellestad S., Jonsson R., Skarstein K. Association between circulating levels of the novel TNF family members APRIL and BAFF and lymphoid organization in primary Sjögren's syndrome. J Clin Immunol 2005, 25:189-201.
74. Nossent J.C., Lester S., Zahra D., Mackay C.R., Rischmueller M. Polymorphism in the 5' regulatory region of the B-lymphocyte activating factor gene is associated with the Ro/La autoantibody response and serum BAFF levels in primary Sjögren's syndrome. Rheumatology (Oxford) 2008, 47:1311-2136.
75. Lavie F., Miceli-Richard C., Ittah M., Sellam J., Gottenberg J.E., Mariette X. B-cell activating factor of the tumour necrosis factor family expression in blood monocytes and T cells from patients with primary Sjögren's syndrome. Scand J Immunol 2008, 67:185-192.
76. Szodoray P., Alex P., Jonsson M.V., Knowlton N., Dozmorov I., Nakken B., et al. Distinct profiles of Sjögren's syndrome patients with ectopic salivary gland germinal centers revealed by serum cytokines and BAFF. Clin Immunol 2005, 117:168-176.
77. Ittah M., Miceli-Richard C., Gottenberg J.E., Lavie F., Lazure T., Ba N., et al. B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjögren's syndrome. Arthritis Res Ther 2006, 8:R51.
78. Daridon C., Devauchelle V., Hutin P., Le Berre R., Martins-Carvalho C., Bendaoud B., et al. Aberrant expression of BAFF by B lymphocytes infiltrating the salivary glands of patients with primary Sjögren's syndrome. Arthritis Rheum 2007, 56:1134-1144.
79. Qian Y., Giltiay N., Xiao J., Wang Y., Tian J., Han S., et al. Deficiency of Act1, a critical modulator of B cell function, leads to development of Sjögren's syndrome. Eur J Immunol 2008, 38:2219-2228.
80. Lavie F., Miceli-Richard C., Ittah M., Sellam J., Gottenberg J.E., Mariette X. Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production. Ann Rheum Dis 2007, 66:700-703.
81. Quartuccio L., Fabris M., Moretti M., Barone F., Bombardieri M., Rupolo M., et al. Resistance to rituximab therapy and local BAFF overexpression in Sjögren's syndrome-related myoepithelial sialadenitis and low-grade parotid b-cell lymphoma. Open Rheumatol J 2008, 2:38-43.
82. Stohl W. Systemic lupus erythematosus and its ABCs (APRIL/BLyS complexes. Arthritis Res Ther 2010, 12(2):111.
83. van Vollenhoven R.F., Petri M.A., Cervera R., Roth D.A., Ji B.N., Kleoudis C.S., et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis 2012, 10.1136/annrheumdis-2011-200937.
84. Ginzler E.M., Wax S., Rajeswaran A., Copt S., Hillson J., Ramos E., et al. Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial. Arthritis Res Ther 2012, 14(1):R33.
85. Ittah M., Miceli-Richard C., Gottenberg J.E., Sellam J., Eid P., Lebon P., et al. Viruses induce high expression of BAFF by salivary gland epithelial cells through TLR- and type-I IFN-dependent and -independent pathways. Eur J Immunol 2008, 38:1058-1064.
86. Mariette X., Ravaud P., Steinfeld S., Baron G., Goetz J., Hachulla E., et al. Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS). Arthritis Rheum 2004, 50:1270-1276.
87. Sankar V., Brennan M.T., Kok M.R., Leakan R.A., Smith J.A., Manny J., et al. Etanercept in Sjögren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis Rheum 2004, 50:2240-2245.
88. Zandbelt M.M., de Wilde P., van Damme P., Hoyng C.B., van de Putte L., van den Hoogen F. Etanercept in the treatment of patients with primary Sjögren's syndrome: a pilot study. J Rheumatol 2004, 31:96-101.
89. Mavragani C.P., Niewold T.B., Moutsopoulos N.M., Pillemer S.R., Wahl S.M., Crow M.K. Augmented interferon-alpha pathway activation in patients with Sjögren's syndrome treated with etanercept. Arthritis Rheum 2007, 56:3995-4004.
90. Norheim K.B., Harboe E., Goransson L.G., Omdal R. Interleukin-1 inhibition and fatigue in primary Sjögren's syndrome - a double blind randomized clinical trial. PLoS One 2012, 7:e30123.
91. Youinou P., Jamin C. The weight of interleukin-6 in B cell-related autoimmune disorders. J Autoimmun 2009, 32:206-210.
92. Wen C.L., Wang C.R., Chuang C.Y., Chen C.Y. Increased production of interleukin-6 and autoantibodies in patients with Sjögren's syndrome. Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi 1992, 25:189-195.
93. Fox R.I., Kang H.I., Ando D., Abrams J., Pisa E. Cytokine mRNA expression in salivary gland biopsies of Sjögren's syndrome. J Immunol 1994, 152:5532-5539.
94. Boumba D., Skopouli F.N., Moutsopoulos H.M. Cytokine mRNA expression in the labial salivary gland tissues from patients with primary Sjögren's syndrome. Br J Rheumatol 1995, 34:326-333.
95. De Vita S., Dolcetti R., Ferraccioli G., Pivetta B., De Re V., Gloghini A., et al. Local cytokine expression in the progression toward B cell malignancy in Sjögren's syndrome. J Rheumatol 1995, 22:1674-1680.
96. Grisius M.M., Bermudez D.K., Fox P.C. Salivary and serum interleukin 6 in primary Sjögren's syndrome. J Rheumatol 1997, 24:1089-1091.
97. Garcíc-Carrasco M., Font J., Filella X., Cervera R., Ramos-Casals M., Sisó A., et al. Circulating levels of Th1/Th2 cytokines in patients with primary Sjögren's syndrome: correlation with clinical and immunological features. Clin Exp Rheumatol 2001, 19:411-415.
98. Szodoray P., Alex P., Brun J.G., Centola M., Jonsson R. Circulating cytokines in primary Sjögren's syndrome determined by a multiplex cytokine array system. Scand J Immunol 2004, 59:592-599.
99. Girón-González J.A., Baturone R., Soto M.J., Márquez M., Macías I., Montes de Oca M., et al. Implications of immunomodulatory interleukins for the hyperimmunoglobulinemia of Sjögren's syndrome. Cell Immunol 2009, 259:56-60.
100. Katsifis G.E., Rekka S., Moutsopoulos N.M., Pillemer S., Wahl S.M. Systemic and local interleukin-17 and linked cytokines associated with Sjögren's syndrome immunopathogenesis. Am J Pathol 2009, 175:1167-1177.
101. Halse A., Tengnér P., Wahren-Herlenius M., Haga H., Jonsson R. Increased frequency of cells secreting interleukin-6 and interleukin-10 in peripheral blood of patients with primary Sjögren's syndrome. Scand J Immunol 1999, 49:533-538.
102. Hartkamp A., Geenen R., Bijl M., Kruize A.A., Godaert G.L., Derksen R.H. Serum cytokine levels related to multiple dimensions of fatigue in patients with primary Sjögren's syndrome. Ann Rheum Dis 2004, 63:1335-1337.
103. Baturone R., Soto M., Marquez M., Macias I., Montes de Oca M., Medina F., et al. Health-related quality of life in patients with primary Sjögren's syndrome: relationship with serum levels of proinflammatory cytokines. Scand J Rheumatol 2009, 38:386-389.
104. d'Elia H.F., Bjurman C., Rehnberg E., Kvist G., Konttinen Y.T. Interleukin 6 and its soluble receptor in a central role at the neuroimmunoendocrine interface in Sjögren syndrome: an explanatory interventional study. Ann Rheum Dis 2009, 68:285-286.
105. Nishimoto N., Miyasaka N., Yamamoto K., Kawai S., Takeuchi T., Azuma J. Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis 2009, 68:1580-1584.
106. Westhovens R., Kremer J.M., Moreland L.W., Emery P., Russell A.S., Li T., et al. Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: a 5-year extended phase IIB study. J Rheumatol 2009, 36:736-742.
107. Hu Y.L., Metz D.P., Chung J., Siu G., Zhang M. B7RP-1 blockade ameliorates autoimmunity through regulation of follicular helper T cells. J Immunol 2009, 182:1421-1428.
108. Chaarani J., Lebwohl M. Alefacept: where it stands today. Expert Opin Drug Metab Toxicol 2010, 6(3):355-361.
109. Lebwohl M., Christophers E., Langley R., Ortonne J.P., Roberts J., Griffiths C.E. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 2003, 139:719-727.
110. Goules A., Tzioufas A.G., Manousakis M.N., Kirou K.A., Crow M.K., Routsias J.G. Elevated levels of soluble CD40 ligand (sCD40L) in serum of patients with systemic autoimmune diseases. J Autoimmun 2006, 26:165-171.
111. Dimitriou I.D., Kapsogeorgou E.K., Moutsopoulos H.M., Manoussakis M.N. CD40 on salivary gland epithelial cells: high constitutive expression by cultured cells from Sjögren's syndrome patients indicating their intrinsic activation. Clin Exp Immunol 2002, 127:386-392.
112. Boumpas D.T., Furie R., Manzi S., Illei G.G., Wallace D.J., Balow J.E., et al. BG9588 Lupus Nephritis Trial Group. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum 2003, 48:719-727.
113. Kalunian K.C., Davis J.C., Merrill J.T., Totoritis M.C., Wofsy D. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002, 46:3251-3258.
114. Reksten T.R., Jonsson M.V., Szyszko E.A., Brun J.G., Jonsson R., Brokstad K.A. Cytokine and autoantibody profiling related to histopathological features in primary Sjögren's syndrome. Rheumatology (Oxford) 2009, 48:1102-1106.
115. Bave U., Nordmark G., Lovgren T., Ronnelid J., Cajander S., Eloranta M.L., et al. Activation of the type I interferon system in primary Sjögren's syndrome: a possible etiopathogenic mechanism. Arthritis Rheum 2005, 52:1185-1195.
116. Bombardieri M., Barone F., Pittoni V., Alessandri C., Conigliaro P., Blades M.C., et al. Increased circulating levels and salivary gland expression of interleukin-18 in patients with Sjögren's syndrome: relationship with autoantibody production and lymphoid organization of the periductal inflammatory infiltrate. Arthritis Res Ther 2004, 6:R447-R456.
117. Sakai A., Sugawara Y., Kuroishi T., Sasano T., Sugawara S. Identification of IL-18 and Th17 cells in salivary glands of patients with Sjögren's syndrome, and amplification of IL-17-mediated secretion of inflammatory cytokines from salivary gland cells by IL-18. J Immunol 2008, 181:2898-2906.
118. Kang K.W., Kim H.O., Kwok S.K., Ju J.H., Park K.S., Sun D.I., et al. Impact of interleukin-21 in the pathogenesis of primary Sjögren's syndrome: increased serum levels of interleukin-21 and its expression in the labial salivary glands. Arthritis Res Ther 2011, 13:R179.
119. Ciccia F., Guggino G., Rizzo A., Ferrante A., Raimondo S., Giardina A., et al. Potential involvement of IL-22 and IL-22-producing cells in the inflamed salivary glands of patients with Sjögren's syndrome. Ann Rheum Dis 2012, 71:295-301.
120. Vosters J.L., Landek-Salgado M.A., Yin H., Swaim W.D., Kimura H., Tak P.P., et al. Interleukin-12 induces salivary gland dysfunction in transgenic mice, providing a new model of Sjögren's syndrome. Arthritis Rheum 2009, 60:3633-3641.
121. Holmes S., Abrahamson J.A., Al-Mahdi N., Abdel-Meguid S.S., Ho Y.S. Characterization of the in vitro and in vivo activity of monoclonal antibodies to human IL-18. Hybridoma 2000, 19:363-367.
122. Baechler E.C., Batliwalla F.M., Karypis G., Gaffney P.M., Ortmann W.A., Espe K.J., et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A 2003, 100(5):2610-2615.
123. Gestermann N., Mekinian A., Comets E., Loiseau P., Puechal X., Hachulla E., et al. STAT4 is a confirmed genetic risk factor for Sjögren's syndrome and could be involved in type 1 interferon pathway signalling. Genes Immun 2010, 11:432-438. Erratum in: Genes Immun 2010;11:446.
124. Miceli-Richard C., Comets E., Loiseau P., Puechal X., Hachulla E., Mariette X. Association of an IRF5 gene functional polymorphism with Sjögren's syndrome. Arthritis Rheum 2007, 56:3989-3994.
125. Merrill J.T., Wallace D.J., Petri M., Kirou K.A., Yao Y., White W.I., et al. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann Rheum Dis 2011, 70:1905-1913.
126. Deshmukh U.S., Nandula S.R., Thimmalapura P.R., Scindia Y.M., Bagavant H. Activation of innate immune responses through Toll-like receptor 3 causes a rapid loss of salivary gland function. J Oral Pathol Med 2009, 38:42-47.
127. Gottenberg J.E., Cagnard N., Lucchesi C., Letourneur F., Mistou S., Lazure T., et al. Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjögren's syndrome. Proc Natl Acad Sci U S A 2006, 103:2770-2775. Erratum in: Proc Natl Acad Sci U S A 2006;103:5242.
128. Spachidou M.P., Bourazopoulou E., Maratheftis C.I., Kapsogeorgou E.K., Moutsopoulos H.M., Tzioufas A.G., et al. Expression of functional Toll-like receptors by salivary gland epithelial cells: increased mRNA expression in cells derived from patients with primary Sjögren's syndrome. Clin Exp Immunol 2007, 147:497-503.
129. Kawakami A., Nakashima K., Tamai M., Nakamura H., Iwanaga N., Fujikawa K., et al. Toll-like receptor in salivary glands from patients with Sjögren's syndrome: functional analysis by human salivary gland cell line. J Rheumatol 2007, 34:1019-1026.
130. Kwok S.K., Cho M.L., Her Y.M., Oh H.J., Park M.K., Lee S.Y., et al. TLR2 ligation induces the production of IL-23/IL-17 via IL-6, STAT3 and NF-kB pathway in patients with primary Sjögren's syndrome. Arthritis Res Ther 2012, 14:R64.
131. Barrat F.J., Coffman R.L. Development of TLR inhibitors for the treatment of autoimmune diseases. Immunol Rev 2008, 223:271-283.
132. Ship J.A., Fox P.C., Michalek J.E., Cummins M.J., Richards A.B. Treatment of primary Sjögren's syndrome with low-dose natural human interferon-alpha administered by the oral mucosal route: a phase II clinical trial. IFN Protocol Study Group. J Interferon Cytokine Res 1999, 19:943-951.
133. Barone F., Bombardieri M., Manzo A., Blades M.C., Morgan P.R., Challacombe S.J., et al. Association of CXCL13 and CCL21 expression with the progressive organization of lymphoid-like structures in Sjögren's syndrome. Arthritis Rheum 2005, 52:1773-1784.
134. Xanthou G., Polihronis M., Tzioufas A.G., Paikos S., Sideras P., Moutsopoulos H.M. " Lymphoid" chemokine messenger RNA expression by epithelial cells in the chronic inflammatory lesion of the salivary glands of Sjögren's syndrome patients: possible participation in lymphoid structure formation. Arthritis Rheum 2001, 44:408-418.
135. Amft N., Curnow S.J., Scheel-Toellner D., Devadas A., Oates J., Crocker J., et al. Ectopic expression of the B cell-attracting chemokine BCA-1 (CXCL13) on endothelial cells and within lymphoid follicles contributes to the establishment of germinal center-like structures in Sjögren's syndrome. Arthritis Rheum 2001, 44:2633-2641.
136. Proudfoot A.E., Power C.A., Schwarz M.K. Anti-chemokine small molecule drugs: a promising future?. Expert Opin Invest Drugs 2010, 19:345-355.
137. Aziz K.E., McCluskey P.J., Wakefield D. Expression of selectins (CD62 E,L,P) and cellular adhesion molecules in primary Sjögren's syndrome: questions to immunoregulation. Clin Immunol Immunopathol 1996, 80:55-66.
138. Turkcapar N., Sak S.D., Saatci M., Duman M., Olmez U. Vasculitis and expression of vascular cell adhesion molecule-1, intercellular adhesion molecule-1, and E-selectin in salivary glands of patients with Sjögren's syndrome. J Rheumatol 2005, 32:1063-1070.
139. Mikulowska-Mennis A., Xu B., Berberian J.M., Michie S.A. Lymphocyte migration to inflamed lacrimal glands is mediated by vascular cell adhesion molecule-1/alpha(4)beta(1) integrin, peripheral node addressin/l-selectin, and lymphocyte function-associated antigen-1 adhesion pathways. Am J Pathol 2001, 159:671-681.
140. Cauli A., Yanni G., Pitzalis C., Challacombe S., Panayi G.S. Cytokine and adhesion molecule expression in the minor salivary glands of patients with Sjögren's syndrome and chronic sialoadenitis. Ann Rheum Dis 1995, 54:209-215.
141. Nishiyama T., Mishima K., Obara K., Inoue H., Doi T., Kondo S., et al. Amelioration of lacrimal gland inflammation by oral administration of K-13182 in Sjögren's syndrome model mice. Clin Exp Immunol 2007, 149:586-595.
142. Tilg H., Kaser A. Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease. Curr Opin Investig Drugs 2010, 11:1295-1304.
143. Humphreys-Beher M.G., Brayer J., Yamachika S., Peck A.B., Jonsson R. An alternative perspective to the immune response in autoimmune exocrinopathy: induction of functional quiescence rather than destructive autoaggression. Scand J Immunol 1999, 49:7-10.
144. Zoukhri D., Kublin C.L. Impaired neurotransmitter release from lacrimal and salivary gland nerves of a murine model of Sjögren's syndrome. Invest Ophthalmol Vis Sci 2001, 42:925-932.
145. Baker O.J., Camden J.M., Redman R.S., Jones J.E., Seye C.I., Erb L., et al. Proinflammatory cytokines tumor necrosis factor-alpha and interferon-gamma alter tight junction structure and function in the rat parotid gland Par-C10 cell line. Am J Physiol Cell Physiol 2008, 295:C1191-C1201.
146. Pitcher J.D., De Paiva C.S., Pelegrino F.S., McClellan A.J., Raince J.K., Pangelinan S.B., et al. Pharmacological cholinergic blockade stimulates inflammatory cytokine production and lymphocytic infiltration in the mouse lacrimal gland. Invest Ophthalmol Vis Sci 2011, 52(6):3221-3227.
147. Melvin J.E., Yule D., Shuttleworth T., Begenisich T. Regulation of fluid and electrolyte secretion in salivary gland acinar cells. Annu Rev Physiol 2005, 67:445-469.
148. Banninger G.P., Cha S., Said M.S., Pauley K.M., Carter C.J., Onate M., et al. Loss of PKCδ results in characteristics of Sjögren's syndrome including salivary gland dysfunction. Oral Dis 2011, 17:601-609.
149. Culp D.J., Zhang Z., Evans R.L. Role of calcium and PKC in salivary mucous cell exocrine secretion. J Dent Res 2011, 90:1469-1476.
150. Bowman S.J. Biologic therapies in Primary Sjögren's syndrome. Curr Pharm Biotechnol 2012, Epub ahead of print.